Search company, investor...
Endeavor Biomedicines company logo

Endeavor Biomedicines

Founded Year



Series B | Alive

Total Raised


Last Raised

$101M | 10 mos ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About Endeavor Biomedicines

Endeavor Biomedicines develops treatments targeting the underlying causes of pulmonary fibrosis. The company develops taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway, that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). By targeting this underlying cause of disease, taladegib has the potential to halt and even reverse IPF.

Headquarters Location

12707 High Bluff Drive Suite 300

San Diego, California, 92130,

United States


Missing: Endeavor Biomedicines's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Endeavor Biomedicines's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Endeavor Biomedicines

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Endeavor Biomedicines is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Endeavor Biomedicines Patents

Endeavor Biomedicines has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Experimental cancer drugs
  • Lung disorders
patents chart

Application Date

Grant Date


Related Topics



Monoclonal antibodies, Experimental cancer drugs, Lung disorders, Rare diseases, Autoimmune diseases


Application Date


Grant Date


Related Topics

Monoclonal antibodies, Experimental cancer drugs, Lung disorders, Rare diseases, Autoimmune diseases



Latest Endeavor Biomedicines News

Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 Mutations for Phase 2 Trial of ENV-101

May 31, 2022

Share xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, announced a partnership that gives patients enrolling in Endeavor’s clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile. The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial. The xCures platform also enables patients to find more suitable treatment options if they are ineligible. “xCures is pleased to partner with Endeavor to help improve outcomes for cancer patients by helping them understand their treatment options and support them and their physician with access” “Endeavor’s partnership with xCures aligns with our patient-first focus and will help guide any patients with cancer who contact us to find the best treatment options for them,” said Anita DiFrancesco, Vice President of Clinical Operations at Endeavor BioMedicines. “We recently dosed the first patient in a Phase 2 study evaluating ENV-101 (taladegib), a small molecule inhibitor of the Hedgehog signaling pathway, in patients with advanced solid tumors harboring PTCH1 loss of function mutations. Endeavor and xCures will work together to identify PTCH1 mutations while also providing alternative treatment options for patients who are ineligible for our trials.” Patients will be registered on the xINFORM platform. Once a patient is registered, xCures will review their cancer history. For patients without molecular profiling, xCures will assist patients with tumor sequencing. After the genomic information is added to a patient’s profile, they will receive a report that lists the best treatment options based on their cancer history and their genomic profile. If the patient has the PTCH1 mutation, they and their physician will be made aware of the option to enroll in the Endeavor clinical trial. Patients whose tumors are negative for the PTCH1 mutation will receive a personalized list of treatment options that they should discuss with their oncologist. “xCures is pleased to partner with Endeavor to help improve outcomes for cancer patients by helping them understand their treatment options and support them and their physician with access,” said Bryan Federowicz , Vice President of Clinical Operations at xCures. “This partnership is an example of how collaboration between industry, doctors and patients can provide the best, uniquely tailored medicine for each individual patient.” ENV-101: Targeting the Hedgehog Signaling Pathway in Oncology and Fibrosis ENV-101 (taladegib), an orally available small molecule inhibitor of the Hedgehog signaling pathway, has already demonstrated preliminary clinical efficacy and safety in nearly 200 subjects enrolled across six completed studies. Initially targeted for a broad group of patients with basal cell carcinoma (BCC), Endeavor is now investigating precision therapy approaches for ENV-101 in multiple types of cancers driven by oncogenic driver mutations in PTCH1, as well as in idiopathic pulmonary fibrosis (IPF). PTCH1 oncogenic driver mutations in the Hedgehog signaling pathway are found in approximately 2% of all cancers. Because of its prevalence across multiple types of cancer, Endeavor plans to enroll patients in a tumor agnostic study that includes any patient with oncogenic hedgehog mutations irrespective of tissue of origin. Endeavor is currently enrolling patients in an open label Phase 2 clinical trial in oncology.

Endeavor Biomedicines Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Endeavor Biomedicines Rank

Endeavor Biomedicines Frequently Asked Questions (FAQ)

  • When was Endeavor Biomedicines founded?

    Endeavor Biomedicines was founded in 2019.

  • Where is Endeavor Biomedicines's headquarters?

    Endeavor Biomedicines's headquarters is located at 12707 High Bluff Drive, San Diego.

  • What is Endeavor Biomedicines's latest funding round?

    Endeavor Biomedicines's latest funding round is Series B.

  • How much did Endeavor Biomedicines raise?

    Endeavor Biomedicines raised a total of $163M.

  • Who are the investors of Endeavor Biomedicines?

    Investors of Endeavor Biomedicines include Longitude Capital, Omega Funds, Piper Sandler, Perceptive Advisors, Revelation Partners and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.